Boston Partners Has $36.20 Million Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Boston Partners boosted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 57.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 400,797 shares of the medical equipment provider’s stock after buying an additional 146,268 shares during the period. Boston Partners’ holdings in Lantheus were worth $36,201,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB acquired a new position in Lantheus during the third quarter worth $25,000. Kestra Investment Management LLC purchased a new stake in shares of Lantheus in the fourth quarter valued at about $27,000. UMB Bank n.a. raised its holdings in shares of Lantheus by 31.5% in the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after purchasing an additional 134 shares during the last quarter. Parkside Financial Bank & Trust raised its holdings in shares of Lantheus by 49.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock valued at $76,000 after purchasing an additional 280 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Lantheus by 118.0% in the fourth quarter. GAMMA Investing LLC now owns 1,018 shares of the medical equipment provider’s stock valued at $91,000 after purchasing an additional 551 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

LNTH opened at $103.28 on Thursday. The firm has a market cap of $7.07 billion, a P/E ratio of 17.18 and a beta of 0.38. The firm has a 50-day moving average of $92.54 and a 200 day moving average of $96.68. Lantheus Holdings, Inc. has a fifty-two week low of $57.78 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Equities research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 64,109 shares of company stock worth $6,110,806 over the last quarter. 1.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several brokerages have recently commented on LNTH. Truist Financial increased their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. The Goldman Sachs Group began coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price for the company. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, JMP Securities restated a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $132.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.